Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of AMT-116 in advanced solid tumors
CTR20240804Phase 2Active
- Sponsor
- PuZhong Discovery
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AMT-116 in Nonhematologic neoplasms, sponsored by PuZhong Discovery. Started May 2024; status: active.
02
Drugs
AMT-116
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20240804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240804.